The Indian Pharmaceutical Industry, from First Principles
The world's pharmacy: ~$55B in revenue (FY25), #1 globally by volume, #3 by value, supplying ~20% of global generics. Understand how value is created across domestic brands, US generics, complex generics, APIs, CDMO and biosimilars — and where Rubicon Research fits.
A plain-English tour of how the Indian pharmaceutical industry actually makes money — its size, its five core business models, and the chain that turns raw chemicals into a medicine a patient takes.
Read top-to-bottom: the cards show how big the industry is, the coloured tiles explain each business model, and the numbered value-chain boxes show where profit and risk sit. Click the cards at the bottom to jump into the live data.
- Generic
- — A copy of an off-patent branded medicine — same drug, much cheaper.
- Formulation
- — Turning the raw active drug (API) into a usable form — tablet, capsule, spray, patch.
- API
- — Active Pharmaceutical Ingredient — the actual drug molecule, made before it's formulated.
- Complex generic
- — A hard-to-copy generic (e.g. inhaler, patch, injectable) with fewer rivals and fatter margins.
- CDMO
- — Contract Development & Manufacturing Org — makes drugs for other companies under contract.
- USFDA
- — The US drug regulator. Its factory inspections can make or break an exporter's revenue.
Industry Revenue
Domestic + exports, ₹ lakh crore
Revenue by Segment
Illustrative FY25E mix
The five business models inside Indian pharma
Each has a distinct margin, capital, regulatory and pricing profile.
Domestic Branded Generics
Brand moatSell branded generics in India through a large field force; doctors prescribe by brand. Sticky, high-margin, but exposed to NLEM/DPCO price control.
US Generics
Scale + filingsFile ANDAs and compete on price in the US. High capital & FDA risk; severe price erosion; the FTF/complex products are where the money is.
Complex Generics
Barriers to entryHard-to-make dosage forms (ER, inhalation, transdermal, device). Fewer competitors, higher margins, formulation-tech advantage — Rubicon's core.
API & Intermediates
Cost + integrationMake the active ingredient at scale. Commodity pricing, China competition; value in backward integration, complex chemistry and China+1.
CDMO / CRDMO
Sticky contractsDevelop & manufacture for innovators. Sticky, high-quality earnings; benefiting from China+1 and innovator outsourcing — but project-lumpy.
Specialty & Biosimilars
Clinical edgeBranded specialty (derm, ophthal, onco) and biosimilars. High R&D and market-access cost, but durable, differentiated, premium economics.
Segment Comparison
Size, growth, risk and Rubicon relevance across the value pools
| Segment | Size (₹L Cr) | Growth | Margin | Reg. Risk | Pricing Risk | Leaders | Rubicon Relevance |
|---|---|---|---|---|---|---|---|
| Domestic Formulations | 2.10 | 9% | 20-32% | Low | High (NLEM/DPCO) | Sun Pharma, Mankind, Cipla | Low — small India footprint |
| US Generics | 0.90 | 7% | 15-30% | High | Very High (erosion) | Sun Pharma, Dr. Reddy's, Aurobindo | Core — primary revenue engine |
| Complex Generics | 0.35 | 14% | 45-65% | High | Medium (fewer players) | Cipla, Lupin, Sun Pharma | Core differentiator — strategic focus |
| API | 0.85 | 8% | 18-31% | Medium | High (commodity) | Divi's, Laurus, Granules | Low — selective backward integration |
| CDMO / CRDMO | 0.45 | 16% | 20-40% | Medium | Low (sticky) | Divi's, Syngene, Suven | Adjacent — formulation-dev services optionality |
| Biosimilars | 0.20 | 18% | 20-35% | High | High | Biocon, Dr. Reddy's, Zydus | None currently |
| Specialty Pharma | 0.30 | 13% | 30-60% | Medium | Low | Sun Pharma, Cipla, Lupin | Emerging — 505(b)(2) optionality |
The pharma value chain
From raw materials to the patient — where margin, regulation and AI leverage concentrate.
Raw Materials & Intermediates
Key starting materials and intermediates, largely sourced from China.
APIs
Active ingredients synthesized at scale; commodity to complex/HPAPI.
Formulation Development
Converting API into a dosage form; where complex-generic value is created.
Clinical / BE Studies
Demonstrating bioequivalence or clinical bridging for filing.
Regulatory Filing
ANDA / 505(b)(2) / eCTD submissions and lifecycle maintenance.
Manufacturing & QC
Commercial-scale GMP manufacturing and quality control.
Distribution & Channel
Wholesalers, GPOs (US), stockists & retail (India).
Prescriber / Payer / Patient
Doctors, hospitals, pharmacies, payers and ultimately patients.
26 listed companies mapped across segments, valuation & returns.
The primary case study: products, pipeline, regulatory and AI roadmap.
35+ scored AI use cases across R&D, regulatory, quality and more.
Headline market figures are sourced; the FY18–FY23 revenue series points are directional reconstructions. Segment value-pools overlap (e.g. complex generics sit within exports) and are illustrative, not additive.